News BMS gets another FDA okay for Opdivo/Yervoy combo Bristol-Myers Squibb has claimed its second FDA approval in just a few days for its Opdivo/Yervoy combination, this time in liver cancer.
News BMS bags a double-quick colorectal cancer approval from FDA The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of colorectal cancer.
News CARGO offloads staff after abandoning lead CAR-T Less than 18 months after its IPO, CAR-T developer CARGO has abandoned its development efforts and slashed around 90% of its staff.
News Sun Pharma buys Checkpoint and its new cancer drug Sun Pharma has agreed to acquire Checkpoint Therapeutics, which recently claimed FDA approval for its first drug but is also running short on cash.
News Can Keytruda finally break into early head and neck cancer? The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.
News FDA looks at Opdivo/Yervoy in first-line colorectal cancer The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.
R&D Driving the drug discovery pipeline: The value of organ-on-a... In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostrzewski, CSO at CN Bio, about single organ-on-a-chip technology.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
